Vector Borne Diseases: Clinical Trials

19 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 terminated. 19 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 319Terminated 19
Phase 26Terminated 6

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
BBV87 Chikungunya vaccine, Normal Saline - Chikungunya
Phase 2 / Phase 3TerminatedInternational Vaccine Institute32102021-08-012025-06-22
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
artemether:lumefantrine (2.5 mg:30 mg) - Plasmodium Falciparum Malaria
Phase 2 / Phase 3TerminatedNovartis Pharmaceuticals282020-12-212026-01-13
Symptomatic Management of Lyme Arthritis
Naproxen, Acetaminophen - Lyme Arthritis, Lyme Disease
Phase 3TerminatedDesiree Neville, MD32019-10-012025-11-17
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
HECT-CL - Cutaneous Leishmaniases
Phase 3TerminatedMedecins Sans Frontieres, Netherlands562017-10-042019-01-16
Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever
Phase 3TerminatedSanofi Pasteur, a Sanofi Company6882016-12-192022-03-25
Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient, Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient - Malaria
Phase 2 / Phase 3TerminatedLondon School of Hygiene and Tropical Medicine612015-12-012016-09-09
The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
abamectin and fenpyroximate - Malaria
Phase 3TerminatedNational Institute for Medical Research, Tanzania49172015-11-092019-02-05
High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
Fluconazole, Meglumine Antimoniate - Cutaneous Leishmaniasis
Phase 3TerminatedHospital Universitário Professor Edgard Santos532014-02-012015-12-02
Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy
Cotrimoxazole, Sulfadoxine-pyrimethamine - Malaria in Pregnancy
Phase 3TerminatedInstitute of Tropical Medicine, Belgium3522009-02-012016-01-18
Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Glucantime®, Zithromax ® - Cutaneous Leishmaniasis
Phase 2 / Phase 3TerminatedAna Rabello482008-06-012014-10-17
Passive Prophylaxis of Lyme Disease Using Permethrin Treated Clothes
Permethrin, Placebo - Lyme Disease
Phase 3TerminatedUniversity of Minnesota612008-06-012020-06-04
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
Pyronaridine - artesunate, Chloroquine - Malaria
Phase 3TerminatedMedicines for Malaria Venture302007-09-062022-01-26
IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.
sulphadoxine/pyrimethamine, Chlorproguanil/dapsone, Sulfadoxine/pyrimethamine - Malaria
Phase 3TerminatedLondon School of Hygiene and Tropical Medicine1122006-07-012017-01-26
CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease
Chloroquine - Chikungunya Virus
Phase 3TerminatedAssistance Publique Hopitaux De Marseille2006-05-012015-08-28
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
controlled nitric oxide releasing patch, meglumine antimoniate - Cutaneous Leishmaniasis
Phase 3TerminatedFundación Cardiovascular de Colombia1782006-05-012010-11-24
Cell Therapy in Chagas Cardiomyopathy
Stem cell, Filgrastime (G-CSF), Standart therapy - Chagas Cardiomyopathy
Phase 3TerminatedMinistry of Health, Brazil1822006-01-012017-03-13
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
Azithromycin/Chloroquine, Sulfadoxine-Pyrimethamine/Chloroquine - Malaria, Falciparum
Phase 2 / Phase 3TerminatedPfizer322004-03-012008-11-03
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
Eflornithine plus Nifurtimox combination therapy - Trypanosomiasis, African
Phase 2 / Phase 3TerminatedEpicentre312002-10-012007-06-21
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d, melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d, nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d - Trypanosomiasis, African
Phase 3TerminatedEpicentre4352001-03-012006-05-26

Narrower conditions

Malaria (6)  ·  Leishmaniasis, Cutaneous (4)  ·  Chikungunya Fever (2)  ·  Lyme Disease (2)  ·  Malaria, Falciparum (2)  ·  Trypanosomiasis, African (2)  ·  Arthritis (1)  ·  Cardiomyopathy, Dilated (1)  ·  Chagas Cardiomyopathy (1)  ·  Dengue (1)  ·  Hyperthermia (1)  ·  Leishmaniasis (1)  ·  Malaria, Vivax (1)  ·  Severe Dengue (1)  ·  Trypanosomiasis (1)

Broader conditions

Infections (19)  ·  Parasitic Diseases (14)  ·  Protozoan Infections (14)  ·  Mosquito-Borne Diseases (10)  ·  Euglenozoa Infections (7)  ·  Skin Diseases (4)  ·  Skin Diseases, Infectious (4)  ·  Skin Diseases, Parasitic (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Arbovirus Infections (3)  ·  Leishmaniasis (3)  ·  RNA Virus Infections (3)  ·  Virus Diseases (3)  ·  Alphavirus Infections (2)

Interventions

Chloroquine (3)  ·  Meglumine Antimoniate (3)  ·  fanasil, pyrimethamine drug combination (3)  ·  Azithromycin (2)  ·  Eflornithine (2)  ·  Acetaminophen (1)  ·  Dengue Vaccines (1)  ·  Fluconazole (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Melarsoprol (1)  ·  Naproxen (1)  ·  Nifurtimox (1)  ·  Permethrin (1)  ·  Saline Solution (1)  ·  Trimethoprim, Sulfamethoxazole Drug Combination (1)

Sponsors

Epicentre (2)  ·  London School of Hygiene and Tropical Medicine (2)  ·  Ana Rabello (1)  ·  Assistance Publique Hopitaux De Marseille (1)  ·  Desiree Neville, MD (1)  ·  Fundación Cardiovascular de Colombia (1)  ·  Hospital Universitário Professor Edgard Santos (1)  ·  Institute of Tropical Medicine, Belgium (1)  ·  International Vaccine Institute (1)  ·  Medecins Sans Frontieres, Netherlands (1)  ·  Medicines for Malaria Venture (1)  ·  Ministry of Health, Brazil (1)  ·  National Institute for Medical Research, Tanzania (1)  ·  Novartis Pharmaceuticals (1)  ·  Pfizer (1)

Countries

Brazil (3)  ·  Colombia (2)  ·  Tanzania (2)  ·  Uganda (2)  ·  United States (2)  ·  Burkina Faso (1)  ·  Costa Rica (1)  ·  Democratic Republic of the Congo (1)  ·  France (1)  ·  Guatemala (1)  ·  Pakistan (1)  ·  Panama (1)  ·  Philippines (1)  ·  South Korea (1)  ·  Thailand (1)

Top investigators

Ana Rabello, MD PhD (1)  ·  Christian F Rueda-Clausen, MD (1)  ·  Christine Manyando, MD (1)  ·  Daniel J Smith, PhD (1)  ·  Daniel Smith, PhD (1)  ·  David R. Boulware, MD, MPH (1)  ·  Desiree NW Neville, MD (1)  ·  Federico A Silva, MD (1)  ·  Gerardo Priotto, MD MPH (1)  ·  Gerardo Priotto, MD, MPH (1)  ·  Gilson Feitosa, MD (1)  ·  Hernando Mosquera, MD (1)  ·  Isabela Ribeiro, MD (1)

Results publications

PMID 19238219, PMID 22523306, PMID 24830749, PMID 27456339, PMID 27803094, PMID 29324864, PMID 34117198, PMID 34521374, PMID 39324693, PMID 41199347

NIH funding

2019 (1)